Skip to content
Pretest: Trop-2 Antibody-Drug Conjugates for the Treatment of TNBC, HR+/HER2- BC, and NSCLC: Advancing Care in the Community Oncology Setting – 4.15.24 Webcast (ID: i889-9)
To assist us in evaluating the effectiveness of this activity, please complete the following pretest.
At the end of this survey, you will be redirected to the Zoom meeting.
*
1.
Contact Information:
(Required.)
Name:
Email:
Institution:
*
2.
Which of the following best describes your profession?
(Required.)
MD/DO
NP/APN
PA
RN
Other (please specify)
*
3.
Which of the following best describes your specialty?
(Required.)
Medical oncology
Hematology/oncology
Internal medicine
Other (please specify)
*
4.
Which of the following best describes your practice setting?
(Required.)
Academic-based
Community-based
Government/VA/DOD
Research
Other (please specify)
*
5.
How confident are you in the management of patients with breast cancer in your practice?
(Required.)
Very confident
Confident
Neutral
Little confidence
No confidence
*
6.
How confident are you in the management of patients with NSCLC in your practice?
(Required.)
Very confident
Confident
Neutral
Little confidence
No confidence
*
7.
Which of the following mechanisms is responsible for the high therapeutic index associated with TROP-2 ADCs?
(Required.)
Targeted cytotoxic effects on TROP2+ tumor cells only
Targeted cytotoxic effects on TROP2+ tumor cells as well as nonspecific destruction of neighboring TROP2+ tumor cells
Targeted cytotoxic effects on TROP2+ tumor cells as well as nonspecific destruction of neighboring TROP2+ and TROP2- tumor cells
*
8.
According to recently presented data from the TropICS-02 trial, treatment of HR+/HER2- mBC with sacituzumab govitecan improved overall survival by what percentage versus chemotherapy?
(Required.)
10 – 20%
20 – 30%
30 – 40%
*
9.
According to recent interim analysis of the TropION-Breast 01 trial, how does the risk for disease progression or death compare between patients with inoperable/metastatic HR-positive, HER2-low or negative treated with datopotamab deruxtecan versus those treated with chemotherapy?
(Required.)
The risk is 10% lower with chemotherapy
The risk is reduced by 20% with datopotamab deruxtecan
The risk is reduced by over 30% with datopotamab deruxtecan
The risk is similar with both treatments
*
10.
According to recent interim analysis of the TropION-Lung01 trial, how does the risk for disease progression or death compare between patients with locally advanced/metastatic NSCLC treated with datopotamab deruxtecan vs those treated with docetaxel?
(Required.)
The risk is reduced by 10% with docetaxel
The risk is reduced by 10% with datopotamab deruxtecan
The risk is reduced by 25% with datopotamab deruxtecan
The risk is similar with both treatments
*
11.
Nadia is a 50-year-old postmenopausal woman diagnosed with de novo metastatic HR+/HER2- BC (IHC 0) 3 years ago with metastases to the bones and liver. First-line treatment comprised aromatase inhibitor therapy and CDK 4/6 inhibitor. She progressed at 30 months. Second-line therapy is everolimus and fulvestrant, with rapid progression. She then receives capecitabine. She presents now with progression after 6 months. Which of the following later-line treatments would you choose?
(Required.)
HER-2-targeted ADC therapy
Trop-2 targeted ADC therapy
Systemic chemotherapy
PARP inhibitor therapy
*
12.
Based on current clinical trial evidence, which of the following describes a patient who would be a suitable candidate for treatment with a Trop-2 ADC?
(Required.)
Treatment-naive patient requiring neoadjuvant therapy for HER2+ BC
Patient with newly-diagnosed TROP2+ locally advanced NSCLC
Treatment-experienced patient with metastatic HR+/HER2-BC
